| 1. |
- Schadendorf, D., et al.
(författare)
-
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : quality-of-life analyses of the METRIC study
- 2014
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 25:3, s. 700-706
-
Tidskriftsartikel (refereegranskat)abstract
- We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib.In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Patients' quality of life (QOL) was assessed at baseline and follow-up visits using the European Organisation for Research and Treatment of Cancer Core QOL questionnaire. In the primary efficacy population (BRAF V600E+, no brain metastases) from baseline to weeks 6 and 12, patients' global health status scores worsened by 4-5 points with chemotherapy but improved by 2-3 points with trametinib. Rapid and substantive reductions in QOL functionality (e.g. role functioning, 8-11 points at weeks 6 and 12) and symptom exacerbation (e.g. fatigue, 4-8 points; nausea and vomiting, 5 points, both at weeks 6 and 12) were observed in chemotherapy-treated patients. In contrast, trametinib-treated patients reported small improvements or slight worsening from baseline at week 12, depending on the functional dimension and symptom. The mean symptom-scale scores for chemotherapy-treated patients increased from baseline (symptoms worsened) for seven of eight symptoms at week 6 (except insomnia) and six of eight symptoms at week 12 (except dyspnea and insomnia). In contrast, at weeks 6 and 12, the mean symptom-scale scores for trametinib decreased from baseline (symptoms improved) for pain (11-12 points), insomnia (10-12 points), and appetite loss (1-5 points), whereas those for diarrhea worsened (15-16 points). Mixed-model repeated-measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements (small to moderate) from baseline in favor of trametinib for global health; physical, role, and social functioning; fatigue; pain; insomnia; nausea and vomiting; constipation; dyspnea; and appetite at weeks 6 and/or 12. QOL results for the intent-to-treat population were consistent. This first QOL assessment for a MEK inhibitor in metastatic melanoma demonstrated that trametinib was associated with less functional impairment, smaller declines in health status, and less exacerbation of symptoms versus chemotherapy.
|
|
| 2. |
- Wang, CH, et al.
(författare)
-
Consensus statement on standard of care for congenital muscular dystrophies
- 2010
-
Ingår i: Journal of child neurology. - : SAGE Publications. - 1708-8283 .- 0883-0738. ; 25:12, s. 1559-1581
-
Tidskriftsartikel (refereegranskat)abstract
- Congenital muscular dystrophies are a group of rare neuromuscular disorders with a wide spectrum of clinical phenotypes. Recent advances in understanding the molecular pathogenesis of congenital muscular dystrophy have enabled better diagnosis. However, medical care for patients with congenital muscular dystrophy remains very diverse. Advances in many areas of medical technology have not been adopted in clinical practice. The International Standard of Care Committee for Congenital Muscular Dystrophy was established to identify current care issues, review literature for evidence-based practice, and achieve consensus on care recommendations in 7 areas: diagnosis, neurology, pulmonology, orthopedics/rehabilitation, gastroenterology/ nutrition/speech/oral care, cardiology, and palliative care. To achieve consensus on the care recommendations, 2 separate online surveys were conducted to poll opinions from experts in the field and from congenital muscular dystrophy families. The final consensus was achieved in a 3-day workshop conducted in Brussels, Belgium, in November 2009. This consensus statement describes the care recommendations from this committee.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Fernandez-Martin, JL, et al.
(författare)
-
COSMOS: the dialysis scenario of CKD-MBD in Europe
- 2013
-
Ingår i: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. - : Oxford University Press (OUP). - 1460-2385. ; 28:7, s. 1922-1935
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
|
|
| 7. |
- Jankowska, M, et al.
(författare)
-
Vitamin B6 and the immunity in kidney transplant recipients
- 2013
-
Ingår i: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. - : Elsevier BV. - 1532-8503. ; 23:1, s. 57-64
-
Tidskriftsartikel (refereegranskat)
|
|
| 8. |
|
|
| 9. |
- Rutkowski, E.W., et al.
(författare)
-
Caixa de ferramentas de metodologias de concertacão para qualificacão profissional
- 2010
-
Ingår i: Brazilian Journal of Labour Studies. - São Paulo : LTR Editora. - 1679-2483. ; IX:2, s. 32-52
-
Tidskriftsartikel (refereegranskat)abstract
- The purpose of this study was developing tools that can support the professional qualification processes in areas and/or topics which are considered essential for a local sustainable development. In order to achieve this goal the study based its analytical and conceptual frameworks on three keystones: the watershed basin, which is basic unit for environmental planning in Brazil; the socioenvironmental sustainability guidelines; and Social Technology strategy.
|
|
| 10. |
- Stefansson, Gunnar, 1963, et al.
(författare)
-
Processes and operations cases
- 2011
-
Ingår i: Sustainable Supply Chain Management: Practical Ideas for Moving Towards Best Practice. - Berlin, Heidelberg : Springer Berlin Heidelberg. - 9783642120220 ; , s. 213-258
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In order to lower logistics costs and increase efficiency in its transportation and warehousing operations, IKEA started an internal competition to reduce unnecessary air in their product packaging. This Air hunting competition focused on removing as much air as possible from packaging and thereby increasing true product volume during transportation and storage. Several IKEA products were identified for packaging development, one being the Glimma tea candle that is described in this best practice documentation. The development of the Glimma tea candle packaging resulted in a 30% increase in products volume for each load unit. Thanks to this packaging development, the efficiency of the transportation and warehouse operations is now much greater and the impact on the environment has decreased significantly.
|
|
